Vascular dementia

被引：1031

作者：

O'Brien, John T. ^{[1
]}

Thomas, Alan ^{[2
,3
]}

机构：

[1] Univ Cambridge, Dept Psychiat, Cambridge CB2 0SP, England

[2] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England

[3] Newcastle Univ, Newcastle Univ Inst Ageing, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England

来源：

LANCET | 2015年 / 386卷 / 10004期

关键词：

WHITE-MATTER CHANGES; MILD COGNITIVE IMPAIRMENT; LATE-LIFE DEPRESSION; DOUBLE-BLIND; ELDERLY INDIVIDUALS; DIAGNOSTIC-CRITERIA; INCIDENT DEMENTIA; ALZHEIMER-DISEASE; NATURAL-HISTORY; RISK-FACTOR;

D O I：

10.1016/S0140-6736(15)00463-8

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Vascular dementia is one of the most common causes of dementia after Alzheimer's disease, causing around 15% of cases. However, unlike Alzheimer's disease, there are no licensed treatments for vascular dementia. Progress in the specialty has been difficult because of uncertainties over disease classification and diagnostic criteria, controversy over the exact nature of the relation between cerebrovascular pathology and cognitive impairment, and the paucity of identifiable tractable treatment targets. Although there is an established relation between vascular and degenerative Alzheimer's pathology, the mechanistic link between the two has not yet been identified. This Series paper critiques some of the key areas and controversies, summarises treatment trials so far, and makes suggestions for what progress is needed to advance our understanding of pathogenesis and thus maximise opportunities for the search for new and effective management approaches.

引用

页码：1698 / 1706

页数：9

共 84 条

[1]

Long term incidence of dementia, predictors of mortality and pathological diagnosis in older stroke survivors [J].

Allan, Louise M. ;

Rowan, Elise N. ;

Firbank, Michael J. ;

Thomas, Alan J. ;

Parry, Stephen W. ;

Polvikoski, Tuomo M. ;

O'Brien, John T. ;

Kalaria, Raj N. .

BRAIN, 2011, 134 :3713-3724

[2]

The cholinergic approach for the treatment of vascular dementia: Evidence from pre-clinical and clinical studies [J].

Amenta, F ;

Di Tullio, MA ;

Tomassoni, D .

CLINICAL AND EXPERIMENTAL HYPERTENSION, 2002, 24 (7-8) :697-713

[3]

[Anonymous], DEM SUPP PEOPL DEM T

[4]

[Anonymous], BMJ

[5]

[Anonymous], BIOMAKERS GENOMIC ME

[6]

Galantamine treatment of vascular dementia: A randomized trial [J].

Auchus, A. P. ;

Brashear, H. R. ;

Salloway, S. ;

Korczyn, A. D. ;

De Deyn, P. P. ;

Gassmann-Mayer, C. .

NEUROLOGY, 2007, 69 (05) :448-458

[7]

Ballard C, 2008, CURR MED RES OPIN, V24, P2561, DOI [10.1185/03007990802328142, 10.1185/03007990802328142 ]

[8]

NINDS AIREN neuroimaging criteria do not distinguish stroke patients with and without dementia [J].

Ballard, CG ;

Burton, EJ ;

Barber, R ;

Stephens, S ;

Kenny, RA ;

Kalaria, RN ;

O'Brien, JT .

NEUROLOGY, 2004, 63 (06) :983-988

[9]

Efficacy and tolerability of donepezil in vascular dementia -: Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial [J].

Black, S ;

Román, GC ;

Geldmacher, DS ;

Salloway, S ;

Hecker, J ;

Burns, A ;

Perdomo, C ;

Kumar, D ;

Pratt, R .

STROKE, 2003, 34 (10) :2323-2330

[10]

ASSOCIATION BETWEEN QUANTITATIVE MEASURES OF DEMENTIA AND OF SENILE CHANGE IN CEREBRAL GREY MATTER OF ELDERLY SUBJECTS [J].

BLESSED, G ;

TOMLINSON, BE ;

ROTH, M .

BRITISH JOURNAL OF PSYCHIATRY, 1968, 114 (512) :797-+

← 1 2 3 4 5 6 7 8 9 →